{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:07:54Z","timestamp":1792796874085,"version":"4.5.0"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000589","name":"Chief Scientist Office","doi-asserted-by":"publisher","award":["CAF\/01\/17"],"award-info":[{"award-number":["CAF\/01\/17"]}],"id":[{"id":"10.13039\/501100000589","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["SP\/19\/3\/34678"],"award-info":[{"award-number":["SP\/19\/3\/34678"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000364","name":"Stroke Association","doi-asserted-by":"publisher","award":["SA CV 20\\100018"],"award-info":[{"award-number":["SA CV 20\\100018"]}],"id":[{"id":"10.13039\/501100000364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["BCDSA\\100005"],"award-info":[{"award-number":["BCDSA\\100005"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L003120\/1"],"award-info":[{"award-number":["MR\/L003120\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RG\/13\/13\/30194; RG\/18\/13\/33946"],"award-info":[{"award-number":["RG\/13\/13\/30194; RG\/18\/13\/33946"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["11607"],"award-info":[{"award-number":["11607"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"hdruk","award":["HDR-9006"],"award-info":[{"award-number":["HDR-9006"]}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00011\/4"],"award-info":[{"award-number":["MC_UU_00011\/4"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000269","name":"Economic and Social Research Council","doi-asserted-by":"publisher","award":["ES\/S007393\/1"],"award-info":[{"award-number":["ES\/S007393\/1"]}],"id":[{"id":"10.13039\/501100000269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thromboses in unusual locations after the Coronavirus Disease 2019 (COVID-19) vaccine ChAdOx1-S have been reported, although their frequency with vaccines of different types is uncertain at a population level. The aim of this study was to estimate the population-level risks of hospitalised thrombocytopenia and major arterial and venous thromboses after COVID-19 vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      In this whole-population cohort study, we analysed linked electronic health records from adults living in England, from 8 December 2020 to 18 March 2021. We estimated incidence rates and hazard ratios (HRs) for major arterial, venous, and thrombocytopenic outcomes 1 to 28 and &gt;28 days after first vaccination dose for ChAdOx1-S and BNT162b2 vaccines. Analyses were performed separately for ages &lt;70 and \u226570 years and adjusted for age, age\n                      <jats:sup>2<\/jats:sup>\n                      , sex, ethnicity, and deprivation. We also prespecified adjustment for anticoagulant medication, combined oral contraceptive medication, hormone replacement therapy medication, history of pulmonary embolism or deep vein thrombosis, and history of coronavirus infection in analyses of venous thrombosis; and diabetes, hypertension, smoking, antiplatelet medication, blood pressure lowering medication, lipid lowering medication, anticoagulant medication, history of stroke, and history of myocardial infarction in analyses of arterial thromboses. We selected further covariates with backward selection.\n                    <\/jats:p>\n                    <jats:p>Of 46 million adults, 23 million (51%) were women; 39 million (84%) were &lt;70; and 3.7 million (8.1%) Asian or Asian British, 1.6 million (3.5%) Black or Black British, 36 million (79%) White, 0.7 million (1.5%) mixed ethnicity, and 1.5 million (3.2%) were of another ethnicity. Approximately 21 million (46%) adults had their first vaccination between 8 December 2020 and 18 March 2021.<\/jats:p>\n                    <jats:p>The crude incidence rates (per 100,000 person-years) of all venous events were as follows: prevaccination, 140 [95% confidence interval (CI): 138 to 142]; \u226428 days post-ChAdOx1-S, 294 (281 to 307); &gt;28 days post-ChAdOx1-S, 359 (338 to 382), \u226428 days post-BNT162b2-S, 241 (229 to 253); &gt;28 days post-BNT162b2-S 277 (263 to 291). The crude incidence rates (per 100,000 person-years) of all arterial events were as follows: prevaccination, 546 (95% CI: 541 to 555); \u226428 days post-ChAdOx1-S, 1,211 (1,185 to 1,237); &gt;28 days post-ChAdOx1-S, 1678 (1,630 to 1,726), \u226428 days post-BNT162b2-S, 1,242 (1,214 to 1,269); &gt;28 days post-BNT162b2-S, 1,539 (1,507 to 1,572).<\/jats:p>\n                    <jats:p>Adjusted HRs (aHRs) 1 to 28 days after ChAdOx1-S, compared with unvaccinated rates, at ages &lt;70 and \u226570 years, respectively, were 0.97 (95% CI: 0.90 to 1.05) and 0.58 (0.53 to 0.63) for venous thromboses, and 0.90 (0.86 to 0.95) and 0.76 (0.73 to 0.79) for arterial thromboses. Corresponding aHRs for BNT162b2 were 0.81 (0.74 to 0.88) and 0.57 (0.53 to 0.62) for venous thromboses, and 0.94 (0.90 to 0.99) and 0.72 (0.70 to 0.75) for arterial thromboses. aHRs for thrombotic events were higher at younger ages for venous thromboses after ChAdOx1-S, and for arterial thromboses after both vaccines.<\/jats:p>\n                    <jats:p>Rates of intracranial venous thrombosis (ICVT) and of thrombocytopenia in adults aged &lt;70 years were higher 1 to 28 days after ChAdOx1-S (aHRs 2.27, 95% CI: 1.33 to 3.88 and 1.71, 1.35 to 2.16, respectively), but not after BNT162b2 (0.59, 0.24 to 1.45 and 1.00, 0.75 to 1.34) compared with unvaccinated. The corresponding absolute excess risks of ICVT 1 to 28 days after ChAdOx1-S were 0.9 to 3 per million, varying by age and sex.<\/jats:p>\n                    <jats:p>The main limitations of the study are as follows: (i) it relies on the accuracy of coded healthcare data to identify exposures, covariates, and outcomes; (ii) the use of primary reason for hospital admission to measure outcome, which improves the positive predictive value but may lead to an underestimation of incidence; and (iii) potential unmeasured confounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, we observed increases in rates of ICVT and thrombocytopenia after ChAdOx1-S vaccination in adults aged &lt;70 years that were small compared with its effect in reducing COVID-19 morbidity and mortality, although more precise estimates for adults aged &lt;40 years are needed. For people aged \u226570 years, rates of arterial or venous thrombotic events were generally lower after either vaccine compared with unvaccinated, suggesting that either vaccine is suitable in this age group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1003926","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T13:25:22Z","timestamp":1645536322000},"page":"e1003926","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":83,"title":["Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4816-8991","authenticated-orcid":true,"given":"William N.","family":"Whiteley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9162-6727","authenticated-orcid":true,"given":"Samantha","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-7353","authenticated-orcid":true,"given":"Jennifer A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2998-7975","authenticated-orcid":true,"given":"Thomas","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0622-6476","authenticated-orcid":true,"given":"Spencer","family":"Keene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5064-446X","authenticated-orcid":true,"given":"Venexia","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8067-5440","authenticated-orcid":true,"given":"Rachel","family":"Denholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0814-0801","authenticated-orcid":true,"given":"Ashley","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efosa","family":"Omigie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Hollings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8776-6719","authenticated-orcid":true,"given":"Emanuele","family":"Di Angelantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9612-7791","authenticated-orcid":true,"given":"Spiros","family":"Denaxas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7937-304X","authenticated-orcid":true,"given":"Angela","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A. C.","family":"Sterne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7725-7520","authenticated-orcid":true,"given":"Cathie","family":"Sudlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CVD-COVID-UK consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"pmed.1003926.ref001","article-title":"Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination","author":"NH Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"pmed.1003926.ref002","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","author":"A Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"pmed.1003926.ref003","article-title":"Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination","author":"M Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"pmed.1003926.ref004","article-title":"Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine","author":"RA Blauenfeldt","year":"2021","journal-title":"J Thromb Haemost"},{"key":"pmed.1003926.ref005","first-page":"373","article-title":"Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: Data resource","author":"A Wood","year":"2021","journal-title":"BMJ"},{"key":"pmed.1003926.ref006","unstructured":"BHF Data Science Centre. Study protocol. 2021. Available from: https:\/\/github.com\/BHFDSC\/Protocols\/blob\/main\/COVID vaccination and risk of arterial and venous event BHF DSC v1.2.pdf"},{"key":"pmed.1003926.ref007","unstructured":"Trusted research environment. [cited 2021 Oct 5]. Available from: https:\/\/digital.nhs.uk\/coronavirus\/coronavirus-data-services-updates\/trusted-research-environment-service-for-england"},{"key":"pmed.1003926.ref008","doi-asserted-by":"crossref","first-page":"f2350","DOI":"10.1136\/bmj.f2350","article-title":"Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study","volume":"346","author":"E Herrett","year":"2013","journal-title":"BMJ"},{"key":"pmed.1003926.ref009","unstructured":"COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events\u2014vaccine\u2019s benefits currently still outweigh risks\u2014Update | European Medicines Agency. [cited 2021 May 10]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/covid-19-vaccine-astrazeneca-prac-investigating-cases-thromboembolic-events-vaccines-benefits"},{"key":"pmed.1003926.ref010","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/s41591-019-0597-x","article-title":"Avoidable flaws in observational analyses: an application to statins and cancer","volume":"25","author":"BA Dickerman","year":"2019","journal-title":"Nat Med"},{"key":"pmed.1003926.ref011","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/ije\/dyaa144","article-title":"Emulating a target trial in case-control designs: an application to statins and colorectal cancer","volume":"49","author":"BA Dickerman","year":"2020","journal-title":"Int J Epidemiol"},{"key":"pmed.1003926.ref012","unstructured":"Office for National Statistics. Estimates of the population for the UK, England and Wales, Scotland and Northern Ireland. 2021 [cited 2021 Oct 5]. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/populationestimatesforukenglandandwalesscotlandandnorthernireland"},{"key":"pmed.1003926.ref013","doi-asserted-by":"crossref","first-page":"n1114","DOI":"10.1136\/bmj.n1114","article-title":"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study","volume":"373","author":"A Potteg\u00e5rd","year":"2021","journal-title":"BMJ"},{"key":"pmed.1003926.ref014","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"M Voysey","year":"2021","journal-title":"Lancet"},{"key":"pmed.1003926.ref015","article-title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","author":"CR Simpson","year":"2021","journal-title":"Nat Med"},{"key":"pmed.1003926.ref016","doi-asserted-by":"crossref","first-page":"n1931","DOI":"10.1136\/bmj.n1931","article-title":"Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study","volume":"374","author":"J Hippisley-Cox","year":"2021","journal-title":"BMJ"},{"key":"pmed.1003926.ref017","first-page":"373","article-title":"Thrombosis after covid-19 vaccination","author":"PR Hunter","year":"2021","journal-title":"BMJ"},{"key":"pmed.1003926.ref018","first-page":"BJGP.2021.0376","article-title":"Trends and clinical characteristics of 57.9 million COVID-19 vaccine recipients: a federated analysis of patients\u2019 primary care records in situ using OpenSAFELY","author":"HJ Curtis","year":"2021","journal-title":"Br J Gen Pract"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003926","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T13:25:58Z","timestamp":1645536358000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003926"}},"subtitle":[],"editor":[{"given":"Suzanne C.","family":"Cannegieter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003926","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.18.21262222","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]}}}